Other · developed by Sutro Biopharma
STRO-006 is a drug studied in head and neck squamous cell carcinoma, non-small cell lung cancer, esophageal cancer, gastric cancer, colorectal cancer, endometrial cancer, urothelial carcinoma and breast cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07807345 | Phase 1 | Head & Neck Squamous Cell Carcinoma | Recruiting | STRO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Breast CancerColorectal CancerEndometrial CancerEsophageal CancerGastric CancerHead & Neck Squamous Cell CarcinomaNon-Small Cell Lung CancerUrothelial Carcinoma (UC)
See STRO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
STRO catalysts and pipeline →